Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162599 | 0.81 | ADORA2A (0.43) | PAX8METKDM4EL3MBTL1ACVR1 | |
| SCHEMBL22253024 | 0.80 | MAPT (0.54) | KDM4EMAPTCYP3A4L3MBTL1ACVR1 | |
| SCHEMBL14346075 | 0.76 | KDM4E (0.49) | KDM4EMAPTCYP1A2SMN1; SMN2NSD2 | |
| SCHEMBL31243256 | 0.75 | LOXL2 (0.60) | PAX8METKDM4ECYP3A4CYP1A2 | |
| SCHEMBL7073831 | 0.75 | LOXL2 (0.60) | PAX8METKDM4ECYP3A4CYP1A2 | |
| SCHEMBL8342933 | 0.74 | PAX8 (0.59) | PAX8METKDM4EMAPTL3MBTL1 | |
| SCHEMBL8098213 | 0.74 | CALM1 (0.55) | — | |
| SCHEMBL10726621 | 0.74 | GPR55 (0.51) | CYP1A2 | |
| SCHEMBL1564325 | 0.72 | MET (0.49) | PAX8METL3MBTL1 | |
| Biphenyl SCHEMBL27852113 | 0.71 | LOXL2 (0.55) | PAX8METKDM4ECYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278530-B2 | Polycyclic amides as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM5 | PAX8 2879/4885MET 349/4885KDM4E 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.